The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

    Adar Poonawalla 'delighted' at low-cost Covishield vaccine announcement; Mahindra says it's time to get the show on the road

    Synopsis

    India Inc sounded quite optimistic about the Monday announcement.

    Agencies
    Anand Mahindra lauded Poonawalla's efforts, and sounded an optimistic note for the vaccine, driven by the positives around its easy storage and transportability.
    2020 has been a year dominated with discussions about the pandemic. From possible treatments for Covid-19, the disease caused by the novel coronavirus, to a vaccine that can put an end to the pandemic. With efforts towards developing a vaccine beginning earlier in the year by dozens of companies, from biotech start-ups to Big Pharma, many of them are now in their later stages.

    Days after a US-German collaboration between Pfizer and BioNTech announced that phase 3 trials for its mRNA vaccine showed 90 per cent efficacy, and US biotech firm Moderna said its vaccine also showed almost 95 percent efficacy, a European project led by the University of Oxford and AstraZeneca, on Monday brought more good cheer. It said that an interim analysis of its phase-3 trials showed their vaccine had an average 70 per cent efficacy in trials involving 23,000 people. The statement said the drug showed a 62 per cent efficacy when people were given two full doses, but this rose to 90 per cent in those given only a half dose initially followed by a full dose.

    The AstraZeneca vaccine is a ray of hope for India, where Adar Poonawalla's Serum Institute, backed by the Gates Foundation, has been manufacturing doses of the vaccine.

    Following the announcement, the 39-year-old Poonawalla who has been headlining through the pandemic and sharing updates on the efforts made at the Serum Institute, took to Twitter to share his excitement. He wrote: "I am delighted to hear that, Covishield, a low-cost, logistically manageable & soon to be widely available, #COVID19 vaccine, will offer protection up to 90% in one type of dosage regime and 62% in the other dosage regime. Further details on this, will be provided this evening."


    Mahindra Group chairman Anand Mahindra lauded Poonawalla's efforts, and sounded an optimistic note for the vaccine, driven by the positives around its easy storage and transportability. Putting his weight behind the cause, the business tycoon said that it was time to get 'this show on the road'.


    RPG Enterprises Chairman Harsh Goenka also gave a thumbs-up to the news as he retweeted Poonawalla.

    The World Health Organization (WHO) has identified 48 "candidate vaccines" at the stage of clinical trials in humans by mid-November, up from 11 in mid-June. Eleven of them are at the most advanced "Phase 3" stage, in which a vaccine's effectiveness is tested on a large scale, generally on tens of thousands of people across several continents.

    Positive results from final stage trials of several vaccine candidates have raised hopes that there is light at the end of the tunnel in the quest to curb a pandemic that has already killed nearly 1.4 million people worldwide.
    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    5 Comments on this Story

    Shri 54 days ago
    Very nice. Smart bets. Cheers
    Shri 54 days ago
    Do medical tourism into India to get Covid Vaccines. Get 10000 dollars and come soon for vacation. Cheers, Peoples of World.
    Sundar Narayanan54 days ago
    Covishield has not even started phase 3 trials in India and mr poonawala is already delighted. What can i say...
    The Economic Times